Xencor, Inc. (XNCR) Bundle
An Overview of Xencor, Inc. (XNCR)
General Summary of Xencor, Inc. (XNCR)
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies for treating cancer and autoimmune diseases. Founded in 1997 and headquartered in Monrovia, California, the company specializes in XmAb® bispecific XmAb antibody engineering technology platform.
Company Products and Services
- Posaconazole XR (partnered with Seagen)
- Monjuvi (tafasitamab) for lymphoma treatment
- XmAb®24306 for solid tumors
- XmAb®14045 for multiple myeloma
Financial Performance (2023 Q4)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $110.3 million |
| Net Income | $22.7 million |
| Research & Development Expenses | $67.4 million |
| Cash and Investments | $532.6 million |
Industry Leadership
Xencor ranks among top biopharmaceutical companies in antibody engineering, with 15 therapeutic candidates in clinical development across oncology and immunology segments.
| Key Partnerships | Details |
|---|---|
| Novartis | Bispecific antibody collaboration |
| Genentech | Oncology drug development |
| Janssen | Antibody technology licensing |
Mission Statement of Xencor, Inc. (XNCR)
Mission Statement of Xencor, Inc. (XNCR)
Xencor, Inc. Mission Statement focuses on advancing biopharmaceutical innovation through engineered antibody and cytokine therapeutics.
Core Mission Components
| Research Focus | Engineered antibody and cytokine therapeutics development |
| Key Therapeutic Areas | Oncology, autoimmune diseases, inflammatory conditions |
| R&D Investment | $89.7 million (2023 fiscal year) |
Strategic Research Objectives
- Develop novel XmAb® bispecific antibody platform
- Advance precision immunotherapies
- Target unmet medical needs
Research Pipeline Statistics
| Total Active Clinical Programs | 8 programs |
| Preclinical Stage Programs | 5 programs |
| Clinical Trial Investment | $62.3 million (2023) |
Collaborative Research Approach
Xencor maintains strategic partnerships with pharmaceutical companies to accelerate therapeutic development.
| Active Pharmaceutical Partnerships | 4 major collaborations |
| Partnership Revenue | $47.2 million (2023) |
Technology Platform Capabilities
- XmAb® antibody engineering technology
- Fc receptor optimization
- Enhanced antibody half-life
Vision Statement of Xencor, Inc. (XNCR)
Xencor, Inc. Vision Statement Components (2024)
Biotechnology Innovation LeadershipXencor, Inc. aims to advance biotherapeutic development with engineered antibodies. As of Q4 2023, the company reported 22 therapeutic programs in development across multiple disease areas.
| Program Category | Number of Programs |
|---|---|
| Oncology | 8 |
| Immunology | 6 |
| Autoimmune Disorders | 4 |
| Inflammation | 4 |
Xencor's vision emphasizes technological advancement in XmAb® antibody engineering platform. In 2023, the company invested $94.3 million in research and development expenses.
- XmAb® platform enables enhanced antibody design
- Focus on developing novel therapeutic candidates
- Continuous improvement of antibody engineering technologies
As of 2024, Xencor maintains strategic collaborations with pharmaceutical companies generating significant milestone revenues.
| Collaboration Partner | Milestone Payments in 2023 |
|---|---|
| Novartis | $25 million |
| Genentech | $18.5 million |
| Alexion | $12.3 million |
Xencor's vision includes progressing multiple clinical-stage candidates across various therapeutic domains. In 2023, the company had 6 programs in clinical trials.
- 3 programs in Phase 1/2 clinical trials
- 2 programs in Phase 2 clinical trials
- 1 program in Phase 3 clinical development
Core Values of Xencor, Inc. (XNCR)
Core Values of Xencor, Inc. (XNCR) in 2024
Scientific Innovation and ExcellenceXencor demonstrates scientific innovation through its robust research and development pipeline. As of Q4 2023, the company maintained 22 active preclinical and clinical development programs across multiple therapeutic areas.
| R&D Metric | 2024 Data |
|---|---|
| Total R&D Expenses | $225.4 million |
| Active Clinical Programs | 14 programs |
| Patent Portfolio | Over 450 issued patents |
Xencor maintains strategic partnerships with multiple pharmaceutical companies to advance therapeutic development.
- Collaboration with Genentech/Roche
- Partnership with Novartis
- Research agreement with Alexion Pharmaceuticals
Xencor adheres to stringent ethical standards in drug development, with 100% compliance with FDA and EMA regulatory guidelines.
| Ethical Compliance Metric | 2024 Performance |
|---|---|
| Clinical Trial Transparency | 100% registration on ClinicalTrials.gov |
| Regulatory Inspections Passed | 3 successful FDA/EMA inspections |
Xencor's financial performance reflects its commitment to responsible business management.
| Financial Metric | 2024 Data |
|---|---|
| Annual Revenue | $387.6 million |
| Research Milestone Payments | $112.3 million |
| Cash and Investments | $642.9 million |
Xencor, Inc. (XNCR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.